Fulgent Genetics (FLGT) Change in Accured Expenses (2015 - 2026)

Fulgent Genetics has disclosed Change in Accured Expenses across 12 years of filings, most recently posting -$2.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$2.1 million, up 71.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (up 302.14% YoY), and the FY2025 annual result was $8.9 million, up 324.97% from the prior year.
• Change in Accured Expenses came in at -$2.1 million for Q1 2026 at Fulgent Genetics, down from $12.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.3 million in Q4 2025 to a low of -$13.2 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is -$177000.0 (2023), against an average of -$315882.4.
• Across the five-year window, Change in Accured Expenses plunged 932.2% in 2024 and jumped 1862.58% in 2025, its largest moves.
• Fulgent Genetics' Change in Accured Expenses stood at $2.0 million in 2022, then surged by 423.32% to $10.4 million in 2023, then tumbled by 93.97% to $628000.0 in 2024, then surged by 1862.58% to $12.3 million in 2025, then tumbled by 117.23% to -$2.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.1 million (Q1 2026), $12.3 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.